A Phase 4 interventional study of Dotarem® and Gadovist®/Gadavist® in Primary Brain Tumor, sponsored by Guerbet. Completed at 32 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-30.
Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,443 studies in Brain Neoplasms with a site in United States — 230 open to participants now, 351 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 48th largest by enrollment of the 1,188 interventional ones that give a count, is one of 54 that started in 2014, is one of 18 in phase 4, and was the 750th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →230 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,443 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 552 · Phase 2 521 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 54 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 279 is above the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,188 interventional studies, 76 across the 191 observational. Of the 994 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,443 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 2 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
140 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,443 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate non-inferiority of Dotarem®-enhanced MRI as compared to Gadovist®/ Gadavist®-enhanced MRI in the diagnosis of brain tumors in terms of overall lesion visualization and characterization (off-site assessment).
270 patients will be randomized between 2 arms defining the sequence of administration of the contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of 14 days in between.
Each patient will, therefore, receive two MRI during his/her participation in the study.
The two arms consist in :
Contrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems.
MRI examinations will be evaluated centrally by blinded independent readers for the main evaluation criterion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
Drug: Dotarem® · Drug: Gadovist®/Gadavist®
Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
Drug: Dotarem® · Drug: Gadovist®/Gadavist®
Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Drug page: Gadobutrol
Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent
Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale: 0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.
Time frame: Up to 15 days after randomization
Adult patients with known or highly suspected primary intracranial tumors and scheduled for a Dotarem®-enhanced MRI were recruited in 27 active centers in 4 countries (Colombia, South Korea, Mexico and United States) from June 2014 to September 2015.
| Milestone | Dotarem®/Gadovist® | Gadovist®/Dotarem® |
|---|---|---|
| Started | 138 | 130 |
| Completed | 138 | 130 |
| Not completed | 0 | 0 |
| Milestone | Dotarem®/Gadovist® | Gadovist®/Dotarem® |
|---|---|---|
| Started | 138 | 130 |
| Completed | 129 | 120 |
| Not completed | 9 | 10 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Other reason | 3 | 2 |
| Milestone | Dotarem®/Gadovist® | Gadovist®/Dotarem® |
|---|---|---|
| Started | 129 | 120 |
| Completed | 129 | 120 |
| Not completed | 0 | 0 |
Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, was assessed by 3 independent off-site readers on a 4-point scale: 0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.
| percentage of patients | Gadovist® (Reader 1) | Dotarem® (Reader 1) | Gadovist® (Reader 2) | Dotarem® (Reader 2) | Gadovist® (Reader 3) | Dotarem® (Reader 3) |
|---|---|---|---|---|---|---|
| Percentage of Patients With Overall Lesion Visualization and Characterization Scored as Good or Excellent | 94.0 | 96.2 | 93.2 | 90.6 | 99.6 | 100.0 |
Collected over From patient inclusion up to 30 min after last contrast agent injection. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dotarem® | — | 1/258 (0.4%) | 42/258 (16.3%) |
| Gadovist® | — | 0/259 (0%) | 44/259 (17%) |
| Total | — | 1/268 (0.4%) | 63/268 (23.5%) |
| Event | Dotarem® | Gadovist® | Total |
|---|---|---|---|
| Aggravation of existing disorderGeneral disorders | 1/258 | 0/259 | 1/268 |
| ComaNervous system disorders | 1/258 | 0/259 | 1/268 |
| Event | Dotarem® | Gadovist® | Total |
|---|---|---|---|
| Injection site painGeneral disorders | 12/258 | 12/259 | 20/268 |
| Medical device painGeneral disorders | 15/258 | 17/259 | 17/268 |
| HeadacheNervous system disorders | 4/258 | 3/259 | 7/268 |
| DizzinessNervous system disorders | 2/258 | 4/259 | 5/268 |
| NauseaGastrointestinal disorders | 2/258 | 3/259 | 5/268 |
| Injection site paraesthesiaGeneral disorders | 2/258 | 1/259 | 2/268 |
| ParaesthesiaNervous system disorders | 2/258 | 0/259 | 2/268 |
| Blood pressure increasedInvestigations | 0/258 | 2/259 | 2/268 |
| Injection site coldnessGeneral disorders | 1/258 | 1/259 | 2/268 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/258 | 1/259 | 2/268 |
All patients receiving at least one injection of contrast agent and with one valid assessment of the primary outcome
| Age, Continuous(years) | Dotarem®/Gadovist® | Gadovist®/Dotarem® | Total |
|---|---|---|---|
| Mean | 52.9 ± 15.2 | 54.4 ± 15.1 | 53.6 ± 15.1 |
| Gender(Participants) | Dotarem®/Gadovist® | Gadovist®/Dotarem® | Total |
|---|---|---|---|
| Female | 87 | 85 | 172 |
| Male | 51 | 45 | 96 |
| Region of Enrollment(participants) | Dotarem®/Gadovist® | Gadovist®/Dotarem® | Total |
|---|---|---|---|
| Colombia | 16 | 16 | 32 |
| United States | 46 | 40 | 86 |
| Korea, Republic of | 24 | 23 | 47 |
| Mexico | 52 | 51 | 103 |
| Body Mass Index(kg per square metre) | Dotarem®/Gadovist® | Gadovist®/Dotarem® | Total |
|---|---|---|---|
| Mean | 27.71 ± 5.35 | 27.62 ± 5.23 | 27.66 ± 5.28 |
The record gives a start of Jun 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gadoterate meglumine · Gadobutrol